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Ovarian cancer is the second most com-
mon type of gynecologic tumor in women, 
with a wordwide incidence of 12.5/100,000 
women. Ovarian cancer presents as a silent 
killer, usually metastasizing throughout 
the abdomen before causing symptoms. 
Consequently, in 63% of patients ovarian 
cancer is detected as FIGO stage III or IV 
disease. This is associated with a poor prog-
nosis, median survival being 36–53 and 
20 months for patients with FIGO stage 
III and IV disease, respectively. Surgery in 
combination with platin-based adjuvant 
chemotherapy remains the cornerstone 
therapeutic modality. If the tumor relapses 
within 6 months of the initial treatment 
with platin-based combination chemother-
apy, the prognosis is very poor.1 Eventually, 
80% of patients that are diagnosed with 
ovarian cancer will die of the disease.
It is thus clear that new treatment 
modalities against ovarian cancer are 
urgently needed. Nowadays, the major 
focus of targeted anticancer therapies is on 
molecular changes and genetic alterations, 
that may offer patients a personalised treat-
ment. However, the heterogeneity of neo-
plastic cells constituting primary neoplastic 
lesions and their metastases is an impor-
tant issue in this respect. In an attempt 
to target rather universal mechanisms of 
tumorigenesis, for example vascular endo-
thelial growth factor (VEGF)-dependent 
vascularization, passive forms of immu-
notherapy based on preformed antibod-
ies have been devised and tested in several 
clinical Phase II trials, mainly resulting 
in a prolongation of progression-free sur-
vival, but associated with a non-negligible 
toxicity.2
Active immunotherapy as a measure to 
treat gynecological malignancies has been 
neglected for a long time and still is in 
its infancy. This approach relies on anti-
cancer vaccines that are able to elicit an 
immune response against tumor-associ-
ated antigens (TAAs) in the human body. 
Several technical aspects of this type of 
immunotherapy should be considered.
First, TAA-based immunotherapeutic 
strategies can be divided into 2 groups: one, 
those that rely on products derived from 
whole cancer cells, including whole cancer-
cell lysates, dendritic cell (DC)/cancer cell 
fusions, total cancer cell RNA or mRNA; 
and two, those that rely on one or more 
specific TAAs. Both have specific advan-
tages and disadvantages, though whole 
cancer-cell approaches are gaining momen-
tum, mostly because they encompass a per-
sonalized and broad range of known and 
unknown tumor antigens (and hence may 
minimize the development of tumor escape 
variants) as well as many proteins shared 
with normal cells, including immunostim-
ulatory cytokines. Moreover, this approach 
provides both MHC class I and II TAA-
derived epitopes. The same advantages do 
not all apply when specific TAAs are used. 
However, side effects should generally be 
milder with TAA-based vaccines than with 
whole cancer cell-based approaches. Over 
60 ovarian cancer-relevant TAAs have been 
studied, including Wilms’ tumor 1 (WT1), 
which is overexpressed by a relevant pro-
portion of these tumors.3
Second, TAAs can be administered as 
pure preparations, i.e., as naked peptides, 
proteins or DNA molecules, or via a car-
rier. DCs are one of the most common 
carriers used in this setting, offering a 
superior platform for stimulating TAA-
specific immune responses in vivo.4
One of the main obstacles against 
the use of synthetic peptides is that only 
patients bearing the HLA type for which 
the peptide is restricted can obtain ben-
efits from this approach. One strategy 
that would circumvent this issue is the 
transfection of TAA-coding mRNA into 
DCs, resulting in transient TAA expres-
sion and subsequent presentation of anti-
genic TAA-derived epitopes on the DC 
surface. The work of several laboratories 
suggests that this approach is an effective, 
if not superior, method to generate immu-
nostimulatory DCs.5 However, in order to 
present TAA-derived epitopes in the con-
text of both MHC class I and II molecules, 
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TAA-coding mRNAs should be modified 
with a lysosome-associated membrane 
protein (LAMP) signal.6 Table 1 gives 
an overview of all clinical studies testing 
DC-based immunotherapy in ovarian can-
cer patients till now. Although DC-based 
immunotherapeutic strategies hold great 
promise, significant clinical responses have 
yet to be achieved. Several studies are ongo-
ing to optimize this approach.
Our research group focuses on two 
types of tumor: high grade glioblastoma 
(HGG)7 and pelvic gynecological malig-
nancies.8,9 In both these settings, DCs 
were chosen as carries of TAAs for vac-
cination. Since HGG has not yet been 
associated with a specific TAA, we chose 
to employ cancer cell lysates. Conversely, 
in uterine and ovarian cancer we chose 
to work with a specific TAA, namely, 
WT1. DCs were loaded with TAA-coding 
mRNA. Both the use of total tumor lysate 
and WT1-coding mRNA offered differ-
ent insights in the tumor biology, behavior 
and immune monitoring. In contrast to 
the rather low clinical responses previ-
ously reported for DC-based immuno-
therapy in this setting, we achieved a 
significant improvement in the clinical 
outcome of HGG patients receiving DCs 
loaded with tumor lysate. Our stud-
ies with gynecological cancer patients 
receiving DCs loaded with WT1-coding 
mRNA generated profound insights into 
the immune responses elicited by the vac-
cine. Therefore, we believe that new stud-
ies testing DC-based immunotherapy in 
ovarian cancer patients should combine 
the whole tumor cell approach with the 
use 1 or 2 defined TAAs.
However, besides focusing on the 
development of immunotherapeutic 
strategies that elicit improved anticancer 
immune responses, it is crucial not to 
neglect the immunosuppressive mecha-
nisms within the tumor microenviron-
ment, which normally hamper antitumor 
immunity. Therefore, combinatorial 
approaches are likely to induce thera-
peutically relevant immune responses, as 
recently demonstrated by Kandalaft et al. 
(Table 1). Specific agents have been devel-
oped to limit immunosuppression by tar-
geting for example regulatory T cells and 
myeloid-derived suppressor cells. In our 
opinion, it is more interesting to harness 
chemotherapeutic agents that are cur-
rently employed against metastatic ovar-
ian cancer. Several of them have indeed 
been shown to exert immunomodulatory 
effects and to induce the immunogenic 
demise of cancer cells.10 The doses and 
combination schedules of these immuno-
chemotherapeutic regimens will however 
be crucial to achieve optimal anticancer 
immune responses.
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Table 1. Overview on DC-based immunotherapy in ovarian cancer
Author and year TAA Type of immunotherapy N° Clinical outcome
Brossart 2000 MuC1 or her2 DCs + peptide 3
1/3 sD > 8 mo; 1/3 
sD during 8 weeks
hernando 2002
Tumor cell 
lysate
DCs + tumor cell lysates and KLh 6 3/6 sD
Loveland 2006
Mannan-MuC1 
fusion protein
DCs + peptide 1 sD
homma 2006 Tumor cells
DC/tumor cell fusions +
rhIL-12
4
1 PD with temporary 
decrease of Ca125
hernando 2007 α-Fr DCs + α-Fr-coding mrNa 1 Prs
Peethambaram 2009 her2
Mix of PBMCs and DCs 
+ recombinant her2-
based fusion protein
4 2/4 sD
Chu 2012
her2 + TerT 
+ PaDre
DCs + peptides +/− cyclophos-
phamide 2 d prior to vaccina-
tion + pneumococcal vaccine
11
2/11 PD during 
vaccination, 3/11 
PD between 
6–26 mo, 6/11 Cr
rhama 2012 p53
Peptide + IL-2 s.c. vs. DCs 
+ peptide + IL-2 i.v.
21
4/20 NeD after 
2 y, 16/20 PD 
(mean 7 mo)
Kandalaft 2013
Tumor cell 
lysate
(a) In 6 patients: bevacizumab i.v. 
+ metronomic cyclophosphamide 
p.o., followed by bevacizumab 
plus vaccination with DCs pulsed 
with tumor cell lysates 
(B) In 3/6 patients, this was 
continued with lymphodepletion 
followed by the transfer of 
autologous vaccine-primed T-cells 
in combination with the vaccine
6
a. 2/6: Pr, 2/6: 
sD, 2/6: PD
B. 1/3: Pr, 1/3: 
sD, 1/3: 1/3: PD
Coosemans 2013 wT1 DCs + wT1-coding mrNa 2
PD, but prolonged 
Os after subsequent 
chemotherapy
Abbreviations: Cr, complete response; DC, dendritic cell; IL, interleukin; KhL, keyhole limpet 
hemocyanin; MuC1, mucin 1; NeD, no evidence of disease; PBMC, peripheral blood mononuclear cell; 
Os, overall survival; PD, progressive disease; Pr, partial remission; rh, recombinant human; sD, stable 
disease; Taa, tumor-associated antigen; TerT, telomerase reverse transcriptase; wT1, wilms’ tumor 
gene 1; y, years; mo, months; s.c., subcutaneous; i.v., intravenous; p.o., per oral; her-2, human epider-
mal growth factor 2; PaDre,  Dr-restricted Th helper epitope.
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